Fluconazole and glucose injection

Fluconazole is a triazole broad-spectrum antifungal drug. It inhibits the reproduction and growth of fungi by highly selectively inhibiting the demethylation of fungal cytochrome P-450 sterol C-14-α-, causing the accumulation of 14-α-methyl sterol in fungi. In vitro tests have shown that this product has antibacterial activity against Cryptococcus neoformans and Candida species. Oral and intravenous injection of fluconazole in animals is effective in the following animal fungal infection models: Candida infection (including systemic candidiasis in immunodeficient animals); Cryptococcus neoformans infection (including intracranial infection); Microsporum and Trichophyton infection, etc. Fluconazole is also effective against Blastomyces dermatitidis infection and Coccidioides immitis infection (including intracranial infection); and is also effective against infections caused by Histoplasma capsulatum in normal animals and immunosuppressed animals.

The main ingredients of this product are fluconazole and glucose.

This product is mainly used for patients with more severe conditions in the following indications: 1. Candidiasis: used to treat oropharyngeal and esophageal Candida infections; disseminated Candidiasis, including Candida vulvovaginitis such as peritonitis, pneumonia, and urinary tract infections. It can also be used to prevent the occurrence of Candida infections in bone marrow transplant patients receiving cytotoxic drugs or radiotherapy. 2. Cryptococcal disease: used to treat new cryptococci other than meninges; when treating cryptococcal meningitis, this product can be used as a maintenance treatment after initial treatment with amphotericin B combined with flucytosine. 3. Coccidioidomycosis. 4. This product can also replace itraconazole for the treatment of blastomycosis and histoplasmosis.

Intravenous drip, the drip time for each 100ml (0.2g) is 30-60 minutes. Adults: (1) Disseminated candidiasis: The first dose is 0.4g, then 0.2g once a day, for 4 weeks, and at least 2 weeks after the symptoms are relieved. (2) Esophageal candidiasis: The first dose is 0.2g, then 0.1g once a day, for 3 weeks, and at least 2 weeks after the symptoms are relieved. Depending on the treatment response, the dose can also be increased to 0.4g once a day. (3) Oropharyngeal candidiasis: The first dose is 0.2g, then 0.1g once a day, for at least 2 weeks. (4) Candidal vulvovaginitis: Single dose, 0.15g. (5) Cryptococcal meningitis: 0.4 g once a day until the condition improves significantly, then 0.2-0.4 g once a day, until the cerebrospinal fluid virus culture turns negative for at least 10-12 weeks. Or: 0.4 g once a day, twice a day, for 2 days, then 0.4 g once a day, the course of treatment is the same as above. For patients with renal insufficiency, if only one dose is needed, no dose adjustment is required; when multiple doses are required, the regular dose should be given on the first and second days, and the dose should be adjusted according to the creatinine clearance rate thereafter, as described in the following table: Creatinine clearance dose 50 Regular dose 11-50 Half of the regular dose Patients undergoing regular dialysis: Administer once after each dialysis Children: The treatment plan has not yet been established. Some data report that the starting dose is 3-6 mg/kg per day, once a day, based on body weight, to treat a small number of pediatric patients aged 2 weeks to 14 years, and the results are safe.

1. Common gastrointestinal reactions, manifested as nausea, vomiting, abdominal pain or diarrhea, etc. 2. Allergic reactions: may manifest as rash, and occasionally severe exfoliative dermatitis (often accompanied by liver damage) and exudative erythema multiforme may occur. 3. Hepatotoxicity: Mild transient elevation of serum aminotransferase may occur during treatment, and symptoms of hepatotoxicity may occasionally occur, especially in patients with serious underlying diseases (such as AIDS and cancer). 4. Headache and dizziness may be seen. 5. Some patients, especially those with serious underlying diseases (such as AIDS and cancer), may have abnormal renal function. 6. Changes in hematological examination indicators such as transient neutropenia and thrombocytopenia in peripheral blood may occasionally occur, especially in patients with serious underlying diseases (such as AIDS and cancer).

Patients with a history of allergy to this product or other azole drugs are contraindicated.

1. When this product is used in combination with isoniazid or rifampicin, the concentration of this product can be reduced. 2. When this product is used in combination with sulfonylurea hypoglycemic drugs such as tolbutamide, chlorbutamide and glipizide, the blood concentration of these drugs can be increased, which may lead to hypoglycemia. Therefore, blood sugar needs to be monitored and the dose of sulfonylurea hypoglycemic drugs needs to be reduced. 3. When high doses of this product are used in combination with cyclosporine, the blood concentration of cyclosporine can be increased, leading to an increased risk of toxic reactions. Therefore, it must be used with caution while monitoring the blood concentration of cyclosporine and adjusting the dose. 4. When this product is used in combination with tissue thiazide, the blood concentration of this product can be increased. 5. When this product is used in combination with theophylline, the blood concentration of theophylline can be increased by about 13%, which can lead to toxic reactions. Therefore, the blood concentration of theophylline needs to be monitored. 6. When this product is used in combination with dicoumarin anticoagulants such as warfarin, it can enhance the anticoagulant effect of dicoumarin anticoagulants and prolong the prothrombin time. Therefore, the prothrombin time should be monitored and used with caution. 7. When this product is used in combination with phenytoin sodium, the blood concentration of phenytoin sodium can be increased. Therefore, the blood concentration of phenytoin sodium needs to be monitored. 8. When this product is used in combination with short-acting benzodiazepines such as midazolam, the blood concentration of midazolam can be significantly increased, and psychomotor effects can occur. This effect is more obvious when taken orally than when injected intravenously. If the patient needs to receive fluconazole and benzodiazepines at the same time, the dose of benzodiazepines should be reduced and the patient should be properly monitored. 9. When this product is taken at the same time with cisapride, adverse cardiac reactions may occur, including torsades de pointes. Patients receiving fluconazole treatment are prohibited from taking cisapride at the same time. 10. When this product is taken simultaneously with tacrolimus, the blood concentration of tacrolimus may increase, which may lead to nephrotoxicity. Patients who take fluconazole and tacrolimus simultaneously should be closely monitored. 11. When this product is taken simultaneously with terfenadine at a daily dose of 400 mg or higher, the plasma concentration of terfenadine may increase significantly. It is forbidden to take fluconazole 400 mg or higher with terfenadine simultaneously. When fluconazole is taken simultaneously with terfenadine at a dose of less than 400 mg per person, the blood concentration of terfenadine should be closely monitored. 12. When this product is taken simultaneously with zidovudine, the blood concentration of the latter may increase, and the occurrence of adverse reactions related to zidovudine should be monitored. 13. When this product is taken simultaneously with astemizole or other drugs metabolized by the cytochrome P-450 system, the serum concentration of these drugs may increase. In the absence of clear data, these drugs should be used with caution and patients should be closely monitored when taken simultaneously with fluconazole. Physicians should be aware of other drug interactions that have not been studied but may occur.

Keep away from light and store in a sealed container.

100ml: Fluconazole 0.2g and glucose 5g

Tentative 12 months

Hubei Kelun Pharmaceutical Co., Ltd.

• Founded in:

  2006-07-04

• Address:

  No. 29 Textile Avenue, Xiantao City, Hubei Province

• Tax NO.:

  91429004790559537U

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view